StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Friday. The brokerage issued a sell rating on the stock.

Separately, Dawson James started coverage on Tonix Pharmaceuticals in a report on Wednesday, February 28th. They set a buy rating and a $3.00 price objective on the stock.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ:TNXP opened at $0.16 on Friday. The business has a 50-day simple moving average of $0.29 and a two-hundred day simple moving average of $0.39. The firm has a market cap of $13.13 million, a price-to-earnings ratio of -0.02 and a beta of 2.21. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $3.31. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.81 and a current ratio of 2.53.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.86) earnings per share (EPS) for the quarter. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million. On average, analysts expect that Tonix Pharmaceuticals will post -3.71 earnings per share for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. Sabby Management LLC purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals makes up approximately 0.5% of Sabby Management LLC’s holdings, making the stock its 6th biggest holding. Sabby Management LLC owned approximately 7.02% of Tonix Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.